stoxline Quote Chart Rank Option Currency Glossary
  
Royalty Pharma plc (RPRX)
32.34  0.09 (0.28%)    02-12 19:58
Open: 32.27
High: 32.56
Volume: 3,662,225
  
Pre. Close: 32.25
Low: 31.73
Market Cap: 14,369(M)
Technical analysis
2025-02-12 4:47:45 PM
Short term     
Mid term     
Targets 6-month :  38.22 1-year :  44.64
Resists First :  32.72 Second :  38.22
Pivot price 31.67
Supports First :  28.42 Second :  25.76
MAs MA(5) :  31.95 MA(20) :  31.38
MA(100) :  27.69 MA(250) :  28.01
MACD MACD :  1 Signal :  1.1
%K %D K(14,3) :  81.5 D(3) :  81
RSI RSI(14): 76.8
52-week High :  32.72 Low :  24.04
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RPRX ] has closed below upper band by 0.8%. Bollinger Bands are 46.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 32.59 - 32.72 32.72 - 32.86
Low: 31.39 - 31.52 31.52 - 31.68
Close: 32.09 - 32.31 32.31 - 32.56
Company Description

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Headline News

Thu, 13 Feb 2025
Royalty Pharma’s Internalization Strategy: Navigating Risks and Uncertainties Ahead of 2025 Transition - TipRanks

Wed, 12 Feb 2025
Royalty Pharma: Delivering Growth With A Positive Story Ahead (NASDAQ:RPRX) - Seeking Alpha

Wed, 12 Feb 2025
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by abrdn plc - MarketBeat

Wed, 12 Feb 2025
Royalty Pharma plc (RPRX) reports earnings - Quartz

Wed, 12 Feb 2025
Royalty Pharma plc SEC 10-K Report - TradingView

Wed, 12 Feb 2025
Royalty Pharma plc (NASDAQ:RPRX) Q4 2024 Earnings Call Transcript - Insider Monkey

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 444 (M)
Shares Float 384 (M)
Held by Insiders 13.1 (%)
Held by Institutions 72.6 (%)
Shares Short 16,630 (K)
Shares Short P.Month 15,650 (K)
Stock Financials
EPS 2.53
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 15.39
Profit Margin 50.5 %
Operating Margin 130.1 %
Return on Assets (ttm) 5.6 %
Return on Equity (ttm) 17.2 %
Qtrly Rev. Growth 5.3 %
Gross Profit (p.s.) 3.98
Sales Per Share 5.1
EBITDA (p.s.) 0
Qtrly Earnings Growth 658.7 %
Operating Cash Flow 2,800 (M)
Levered Free Cash Flow -2,120 (M)
Stock Valuations
PE Ratio 12.73
PEG Ratio 0
Price to Book value 2.1
Price to Sales 6.32
Price to Cash Flow 5.13
Stock Dividends
Dividend 0.2
Forward Dividend 0
Dividend Yield 0.6%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android